Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.49 |
| ▸ | DPP4 | P27487 | 4/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.46 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122448 | 0.79 | DPP8 (0.68) | NOTUMDPP8DPP9DPP7DPP4 | |
| SCHEMBL6230600 | 0.76 | MAPK1 (0.45) | NOTUMDPP8DPP9DPP7DPP4 | |
| SCHEMBL8206656 | 0.76 | NAMPT (0.65) | NOTUMDPP8DPP9DPP7DPP4 | |
| SCHEMBL16356396 | 0.74 | NOTUM (0.58) | NOTUMDPP8DPP9DPP7DPP4 | |
| SCHEMBL4779078 | 0.74 | DPP8 (0.71) | NOTUMDPP8DPP9DPP7DPP4 | |
| SCHEMBL4779080 | 0.74 | DPP8 (0.71) | NOTUMDPP8DPP9DPP7DPP4 | |
| SCHEMBL4775055 | 0.73 | DPP7 (0.66) | NOTUMDPP8DPP9DPP7DPP4 | |
| SCHEMBL4775064 | 0.73 | DPP7 (0.66) | NOTUMDPP8DPP9DPP7DPP4 | |
| SCHEMBL4779218 | 0.72 | DPP8 (0.69) | NOTUMDPP8DPP9DPP7DPP4 | |
| SCHEMBL27283804 | 0.72 | NOTUM (0.55) | NOTUMDPP8DPP9DPP7DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | NOTUM 1656/4885DPP8 3805/4885DPP9 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.